Abstract:The Bayesian optimal interval (BOIN) design is a novel phase I trial design for finding the maximum tolerated dose (MTD). It can be used to conduct both single-agent and drug-combination trials. The BOIN design is motivated by the top priority and concern of clinicians, which is to effectively treat patients and minimize the chance of exposing them to subtherapeutic or overly toxic doses. The most important advantage of the BOIN design is that it is easy to implement in practice and has superior operating characteristics. The BOIN design is algorithm-based and thus can be implemented in a way similar to the traditional “3+3” design. The performance of the BOIN design is comparable to that of the continual reassessment method (CRM, one of the best performing model-based phase I trial designs) in terms of selecting the MTD, but has a lower risk of assigning patients to subtherapeutic or overly toxic doses (i.e., better patient ethics). The idea behind the BOIN design is straightforward. The conduct of phase I trials can be viewed as a sequence of decision-making steps of dose assignment for patients who are sequentially enrolled into a trial. At each moment of decision making, based on the observed data, we take one of three actions: escalate, deescalate or retain the current dose. Under the standard assumption that efficacy monotonically increases with toxicity (for cytotoxic agents), an ideal trial design would escalate the dose when the current dose is below the MTD in order to avoid treating a patient at a subtherapeutic dose level; deescalate the dose when the current dose is above the MTD in order to avoid exposing a patient to an overly toxic dose; and retain the same dose level when the current dose is equal (or close) to the MTD. However, such an ideal design is not available in practice because we do not know whether the current dose is actually below, above or equal (or close) to the MTD, and need to

Optimal Approximate Designs for Comparison with Control in Dose-Escalation Studies

Adaptive designs for identifying optimal biological dose for molecularly targeted agents.

A Bayesian Quasi-Likelihood Design for Identifying the Minimum Effective Dose and Maximum Utility Dose in Dose-Ranging Studies

An Adaptive Trial Design to Optimize Dose-Schedule Regimes with Delayed Outcomes

Optimal designs for dose–response models with linear effects of covariates

Seamless Phase II/III Design: a Useful Strategy to Reduce the Sample Size for Dose Optimization

AIDE: Adaptive intrapatient dose escalation designs to accelerate Phase I clinical trials

Optimal designs for active controlled dose finding trials with efficacy-toxicity outcomes

Bayesian hybrid dose-finding design in phase I oncology clinical trials.

Sequential Continual Reassessment Method for Two-Dimensional Dose Finding.

Comparative Review of Novel Model‐assisted Designs for Phase I Clinical Trials

Comparative review of novel model-assisted designs for phase I clinical trials.

On the Relative Efficiency of Model-Assisted Designs: a Conditional Approach.

Statistical and practical considerations in planning and conduct of dose-optimization trials

Optimal experimental designs for treatment contrasts in heteroscedastic models with covariates

Response-adaptive dose-finding under model uncertainty

Optimal designs for comparing curves

Designing Dose-Optimization Studies in Cancer Drug Development: Discussions with Regulators

Time-to-event Model-Assisted Designs for Dose-Finding Trials with Delayed Toxicity

Statistical Tutorial for Using Bayesian Optimal Interval (BOIN) Design for Phase I Single-Agent and Drug-Combination Trials

Bayesian Optimal Interval Designs for Phase I Clinical Trials